DBV Technologies' MACD Death Cross signals bearish trend with Bearish Marubozu.

According to DBV Technologies' 15-minute chart, a MACD Death Cross and Bearish Marubozu pattern has emerged, indicating that the stock price is likely to continue its downward trend. This suggests that sellers are currently dominating the market, and bearish momentum is expected to persist.

The peanut allergy market is poised for significant growth, driven by advancements in treatment options and increased awareness. According to DelveInsight's report [1], the market size for peanut allergy in the 7MM (United States, EU4, and Japan) was USD 400 million in 2024 and is expected to witness a substantial increase, with a CAGR of 16% during the study period from 2020 to 2034.

Key drivers for this growth include the increased usage of approved therapies, the expected entry of novel emerging therapies, and a slight increase in diagnosis rates. The report highlights that in 2024, the US alone reported approximately 5.1 million prevalent cases of peanut allergy, with only about 50% of affected individuals receiving treatment. This indicates a significant gap in patient care and therapy adoption.

One of the notable developments in the market is the introduction of Viaskin Peanut Patch by DBV Technologies. This epicutaneous immunotherapy (EPIT) delivers trace amounts of peanut protein via a skin patch to promote desensitization in allergic individuals. The therapy has received both Fast Track and Breakthrough Therapy Designations from the US FDA and is currently being assessed in a Phase III clinical trial involving peanut-allergic children aged 4 to 7. DBV Technologies expects to share top-line data from the VITESSE trial (NCT05741476) in Q4 2025 [1].

Another significant advancement is the approval of XOLAIR (omalizumab) by Novartis, which offers a new option for food allergy treatment, including peanut allergy. However, the high annual cost of XOLAIR, ranging from USD 30,000 to USD 60,000, poses a barrier to affordability and patient access, potentially hindering its broader adoption [1].

The market is also witnessing a rise in the number of diagnosed cases of peanut allergy, with mild-to-moderate cases contributing majorly in 2024. This trend is expected to continue, driven by the increasing investment and partnerships in the allergy treatment space. However, several factors may impede the growth of the market, including the slow uptake of existing therapies, underdiagnosis of mild patients, and the limited number of active drugs in the pipeline [1].

In conclusion, the peanut allergy market is experiencing significant growth and innovation, driven by advancements in treatment options and increased awareness. While challenges remain, the market is poised for continued expansion, offering opportunities for investors and healthcare professionals alike.

References:
[1] https://www.prnewswire.com/news-releases/peanut-allergy-market-set-to-grow-at-a-16-cagr-during-the-study-period-20202034-owing-to-current-usage-of-epinephrine-anticipated-usage-of-xolair-in-adults-palforzia-in-toddlers-and-expected-entry-of-viaskin-peanut-patches--302506490.html